Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Straley

Showing results (171-180 of 183) with videos related to

Pageof 19
Sort By:
ACS Medicinal Chemistry Letters|February 20, 2020
Vorasidenib (AG-881): A First-in-Class, Brain-Penetrant Dual Inhibitor of Mutant IDH1 and 2 for Treatment of GliomaZenon Konteatis, Erin Artin, Brandon Nicolay, et al.
Nature|July 22, 2014
Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancerSupriya K Saha, Christine A Parachoniak, Krishna S Ghanta, et al.
Neuro-Oncology|December 23, 2015
Integration of 2-hydroxyglutarate-proton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenase-mutant gliomaMacarena I de la Fuente, Robert J Young, Jennifer Rubel, et al.
Science (New York, N.Y.)|April 6, 2013
Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiationFang Wang, Jeremy Travins, Byron DeLaBarre, et al.
Journal of Inherited Metabolic Disease|July 30, 2016
A small molecule inhibitor of mutant IDH2 rescues cardiomyopathy in a D-2-hydroxyglutaric aciduria type II mouse modelFang Wang, Jeremy Travins, Zhizhong Lin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 31, 2014
Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinomaDarrell R Borger, Lipika Goyal, Thomas Yau, et al.
ACS Medicinal Chemistry Letters|April 20, 2018
Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant CancersJaneta Popovici-Muller, René M Lemieux, Erin Artin, et al.
Cancer Discovery|February 15, 2017
AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic <i>IDH2</i> MutationsKatharine Yen, Jeremy Travins, Fang Wang, et al.
The Journal of Experimental Biology|March 2, 2022
Scaling of maneuvering performance in baleen whales: larger whales outperform expectationsPaolo S Segre, William T Gough, Edward A Roualdes, et al.
Cancer Cell|July 19, 2016
Mutant IDH1 Downregulates ATM and Alters DNA Repair and Sensitivity to DNA Damage Independent of TET2Satoshi Inoue, Wanda Y Li, Alan Tseng, et al.
Pageof 19

Showing results (171-180 of 183) with videos related to

Sort By:
Pageof 19
ACS Medicinal Chemistry Letters|February 20, 2020
Vorasidenib (AG-881): A First-in-Class, Brain-Penetrant Dual Inhibitor of Mutant IDH1 and 2 for Treatment of GliomaZenon Konteatis, Erin Artin, Brandon Nicolay, et al.
Nature|July 22, 2014
Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancerSupriya K Saha, Christine A Parachoniak, Krishna S Ghanta, et al.
Neuro-Oncology|December 23, 2015
Integration of 2-hydroxyglutarate-proton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenase-mutant gliomaMacarena I de la Fuente, Robert J Young, Jennifer Rubel, et al.
Science (New York, N.Y.)|April 6, 2013
Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiationFang Wang, Jeremy Travins, Byron DeLaBarre, et al.
Journal of Inherited Metabolic Disease|July 30, 2016
A small molecule inhibitor of mutant IDH2 rescues cardiomyopathy in a D-2-hydroxyglutaric aciduria type II mouse modelFang Wang, Jeremy Travins, Zhizhong Lin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 31, 2014
Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinomaDarrell R Borger, Lipika Goyal, Thomas Yau, et al.
ACS Medicinal Chemistry Letters|April 20, 2018
Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant CancersJaneta Popovici-Muller, René M Lemieux, Erin Artin, et al.
Cancer Discovery|February 15, 2017
AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic <i>IDH2</i> MutationsKatharine Yen, Jeremy Travins, Fang Wang, et al.
The Journal of Experimental Biology|March 2, 2022
Scaling of maneuvering performance in baleen whales: larger whales outperform expectationsPaolo S Segre, William T Gough, Edward A Roualdes, et al.
Cancer Cell|July 19, 2016
Mutant IDH1 Downregulates ATM and Alters DNA Repair and Sensitivity to DNA Damage Independent of TET2Satoshi Inoue, Wanda Y Li, Alan Tseng, et al.
Pageof 19